🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Muscle Deterioration in Hospitalized Cancer Patient

RecruitingNAAges 18 Years - anyAllUniversity of Salamanca
NCT07387770 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Cancer cachexia and skeletal muscle deterioration represent significant challenges in oncology, affecting up to 42% of cancer patients and correlating with poor clinical outcomes, increased treatment toxicity, and reduced overall survival. Early identification of patients at risk through comprehensive musculoskeletal assessment is essential for timely therapeutic intervention. This paper presents a detailed protocol for the longitudinal evaluation of skeletal muscle deterioration in hospitalized cancer patients using an integrated, multimodal approach. The protocol combines validated questionnaires (SARC-F, MSAS, EORTC QLQ-C30, and PSQI), functional measurements (handgrip strength), body composition analysis (bioelectrical impedance analysis), neuromuscular assessment (surface electromyography), and serum biomarkers (basic panel approach). The study aims to recruit 45-50 patients with

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age: more than 18 years * Confirmed malignant neoplasm diagnosis * Hospitalization anticipated for at least 4 days * Capacity to provide informed consent and complete questionnaires * ECOG performance status 0-3 * Ability to perform voluntary contractions of upper and lower extremities Exclusion Criteria: * Medical contraindications to strength testing (recent fractures, acute injuries) - Severe neurological impairment precluding functional assessment * Implanted electronic devices (relative contraindication for bioimpedance) * Severe cognitive impairment preventing questionnaire completion * Extensive skin lesions preventing electrode placement for sEMG
💊

What it tests

  • Screenig Phase
📍

Where

1 site
Hospital Universitario de Salamanca
Salamanca, Spain
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy